Blood proteomics of paediatric bronchiolitis obliterans syndrome after haematopoietic cell transplant
Year: 2025
Type: article
Study design: Observational Study
Abstract: Background The molecular determinants for lung graft- versus -host disease-associated bronchiolitis obliterans syndrome (BOS) are poorly understood, and biomarkers in children following haematopoietic stem cell transplant do not exist. To address this gap, we analysed plasma samples from 21 paediatric stem cell transplant recipients prior to and at diagnosis of BOS. Methods Participants included three cohorts: seven with BOS; seven sex-, age- and timepoint-matched with severe graft- versus -host disease alone; and seven sex-, age- and timepoint-matched transplant recipients without BOS or other graft- versus -host disease. Results Our proteomic approach evaluated the expression of 190–12 588 protein isoforms, depending on statistical stringency, and distinguished the three cohorts of paediatric patients prior to and at the time of BOS diagnosis. Differences included proteins that regulate chromatin modification, acute phase signalling, complement, fibrosis, hypoxia, serine protease inhibition, vitamin transport, glucocorticoid receptor transactivation and blood coagulation pathways. A subset of newly discovered proteins was cross-platform validated by ELISA in a larger cohort of paediatric patients 14 (n=107), 30 (n=108), 60 (n=108) and 100 (n=134) days post-transplant. Pathways analysis highlighted potential therapeutics including azithromycin, statins, pazopanib and cediranib. Conclusion Our strategy offers a potential for early diagnosis and the identification of interventions for paediatric stem cell transplant-associated graft- versus -host disease and BOS.
Source: ERJ Open Research
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Keywords: bronchiolitis obliterans syndrome, hematopoietic stem cell transplantation, pediatric transplant recipients, graft-versus-host disease, blood proteomics, plasma protein biomarkers, early diagnosis, chromatin modification, fibrosis, hypoxia, serine protease inhibition, glucocorticoid receptor, azithromycin, statins, pazopanib, cediranib
Open Access status: gold
Estimated APC paid: $808
Awards: Predictive Molecular Markers of Lung Function Decline, Thrombotic microangiopathy (TMA) associated MODS after stem cell transplantation, G1883364948, Commercial Translation of Biomarker-based Platform for Personalized Forecasting of Rapid Lung Function Decline, MIDAS: MIcroangiopathy, endothelial Damage in Adults undergoing Stem cell transplantation, Viral and host predictors of BK polyomavirus associated hemorrhagic cystitis, G9000245648, Penetrating the “Black box”: Prediction of early Bronchiolitis obliterans in Pediatric Hematopoietic Stem Cell Transplant Recipients, TRANSPIRE: A Prospective Cohort Study of Lung Injury After Hematopoietic Stem Cell Transplant in Children., Imaging and Molecular Phenotyping of Cystic Fibrosis Lung Disease
OpenAlex ID: W4416995331
